Private company Colibri Heart Valve LLC reported the first two enrollees in the clinical early feasibility study of its second-generation expandable 24 mm and 27 mm transcatheter aortic valve (TAVI) system. The "package-to-patient" device has built on the earlier system that included a premounted, replacement aortic heart valve already precrimped to the balloon catheter, sheathed and sterilized so that it can be used directly from packaging. The newest device allows for adoption by additional patients, such as those with bicuspid aortic valves.